Pramanik Dipankar
Department of Chemistry, Haldia Government College, Debhog, Haldia, West Bengal 721657, India.
Anticancer Agents Med Chem. 2023;23(6):642-657. doi: 10.2174/1871520623666221031105432.
Antibody-Drug Conjugates (ADCs) are basically a targeted drug delivery system where tumour antigenspecific antibodies are used for targeting particular tumor cells and cytotoxic materials are conjugated with it by a linker molecule. Till now, twelve ADCs have been approved by FDA for clinical use. Majority of the approved ADCs are against hematological cancer. Here in this review, we will discuss the combinations of targeted ligands (antigen) specific antibodies, different types of cytotoxic drugs (payload/warheads) and linker moieties which are being used for the development of successful FDA approved ADCs. We will discuss new ADC formulations which completed clinical trials or underwent advance phases of clinical trials against different types of solid tumours. New ADC formulation or recently developed its prototypes against solid tumour models in preclinical studies will be discussed precisely in this review article.
抗体药物偶联物（ADCs）基本上是一种靶向给药系统，其中肿瘤抗原特异性抗体用于靶向特定肿瘤细胞，细胞毒性物质通过连接分子与之偶联。到目前为止，已有12种ADCs被美国食品药品监督管理局（FDA）批准用于临床。大多数已批准的ADCs用于治疗血液系统癌症。在本综述中，我们将讨论用于开发成功获得FDA批准的ADCs的靶向配体（抗原）特异性抗体、不同类型的细胞毒性药物（有效载荷/弹头）和连接部分的组合。我们将讨论已完成针对不同类型实体瘤的临床试验或已进入临床试验后期阶段的新ADCs制剂。本文将详细讨论新的ADCs制剂或最近在临床前研究中针对实体瘤模型开发的原型。
